Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics

Annals of the New York Academy of Sciences

Volumn 1032, Issue , 2004, Pages 297-298

  Liu Seifert, Hong ^a   Kinon, Bruce J ^a   Ahl, Jonna ^a   Lamberson, Shaw ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bone density; Fasting serum lipids; Olanzapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OSTEOCALCIN; PROLACTIN; RISPERIDONE;

ADULT; AGED; AGING; BONE DENSITY; BONE METABOLISM; CHRONIC DISEASE; CONFERENCE PAPER; FEMALE; HUMAN; HYPERPROLACTINEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OSTEOPENIA; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 14544271789     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1314.044     Document Type: Conference Paper

References (2)

1. HALBREICH, U., B.J. KINON, J.A. GILMORE, et al. 2003. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse events. Psychoneuroendocrinology 28: 53-67.
2. KINON, B.J., J.A. GILMORE, H. LIU & U.M. HALBREICH. 2003. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (Suppl 2): 55-68.